LENZ Therapeutics (LENZ) Assets (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Assets of $272.5 million for Q1 2026, up 35.42% year-over-year from $201.3 million in Q1 2025, and down 10.9% quarter-over-quarter from $305.9 million in Q4 2025.
LENZ Therapeutics (LENZ) Assets (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Assets for 7 consecutive years, with $272.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 35.42% year-over-year to $272.5 million; the TTM figure through Mar 2026 stood at $272.5 million (up 35.42% YoY), while the FY2025 annual figure was $305.9 million, up 42.07% from the prior year.
- Assets eased to $272.5 million in Q1 2026 per LENZ's latest filing, from $305.9 million in the prior quarter.
- Across five years, Assets topped out at $378.6 million in Q1 2022 and bottomed at $70.4 million in Q4 2023.
- Historically, Assets has averaged $258.2 million across 5 years, with a median of $266.2 million in 2023.
- Annual changes were most pronounced in 2023 — Assets tumbled 78.14% — and 2024, when it jumped 205.93%.
- LENZ Therapeutics' Assets stood at $321.9 million in 2022, then sank by 78.14% to $70.4 million in 2023, then surged by 205.93% to $215.3 million in 2024, then soared by 42.07% to $305.9 million in 2025, then retreated by 10.9% to $272.5 million in 2026.
- Business Quant data shows LENZ's Assets at $272.5 million in Q1 2026, $305.9 million in Q4 2025, and $210.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.82 Bn |
| 10 | LENZ Therapeutics | 148.40 Mn | 148.40 Mn | 5.21 Mn | 236.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 236.60 Mn |
| Mar 31, 2026 | 272.54 Mn |
| Dec 31, 2025 | 305.88 Mn |
| Sep 30, 2025 | 210.70 Mn |
| Jun 30, 2025 | 217.33 Mn |
| Mar 31, 2025 | 201.25 Mn |
| Dec 31, 2024 | 215.30 Mn |
| Sep 30, 2024 | 224.01 Mn |
| Jun 30, 2024 | 202.64 Mn |
| Mar 31, 2024 | 217.32 Mn |
| Dec 31, 2023 | 70.38 Mn |
| Sep 30, 2023 | 266.23 Mn |
| Jun 30, 2023 | 287.04 Mn |
| Mar 31, 2023 | 310.00 Mn |
| Dec 31, 2022 | 321.90 Mn |
| Sep 30, 2022 | 334.85 Mn |
| Jun 30, 2022 | 353.79 Mn |
| Mar 31, 2022 | 378.61 Mn |
| Dec 31, 2021 | 401.99 Mn |
| Sep 30, 2021 | 416.15 Mn |